Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells

Drugs that target novel surfaces on the androgen receptor (AR) and/or novel AR regulatory mechanisms are promising alternatives for the treatment of castrate-resistant prostate cancer. The 52 kDa FK506 binding protein (FKBP52) is an important positive regulator of AR in cellular and whole animal models and represents an attractive target for the treatment of prostate cancer. We used a modified receptor-mediated reporter assay in yeast to screen a diversified natural compound library for inhibitors of FKBP52-enhanced AR function. The lead compound, termed MJC13, inhibits AR function by preventing hormone-dependent dissociation of the Hsp90-FKBP52-AR complex, which results in less hormone-bound receptor in the nucleus. Assays in early and late stage human prostate cancer cells demonstrated that MJC13 inhibits AR-dependent gene expression and androgen-stimulated prostate cancer cell proliferation.

[1]  J. Katzenellenbogen,et al.  Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs). , 2010, Molecular endocrinology.

[2]  H. Frierson,et al.  FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells , 2010, Molecular and Cellular Biology.

[3]  W. Shou,et al.  FKBP51 and Cyp40 are Positive Regulators of Androgen-dependent Prostate Cancer Cell Growth and the Targets of FK506 and Cyclosporin A , 2009, Oncogene.

[4]  R. Guy,et al.  A High-Throughput Ligand Competition Binding Assay for the Androgen Receptor and Other Nuclear Receptors , 2009, Journal of biomolecular screening.

[5]  D. Toft,et al.  Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. , 2008, Molecular endocrinology.

[6]  J. Buchner,et al.  Noncatalytic Role of the FKBP52 Peptidyl-Prolyl Isomerase Domain in the Regulation of Steroid Hormone Signaling , 2007, Molecular and Cellular Biology.

[7]  Phuong Nguyen,et al.  A surface on the androgen receptor that allosterically regulates coactivator binding , 2007, Proceedings of the National Academy of Sciences.

[8]  P. Nelson,et al.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.

[9]  M. Cohn,et al.  Essential Role for Co-chaperone Fkbp52 but Not Fkbp51 in Androgen Receptor-mediated Signaling and Physiology* , 2007, Journal of Biological Chemistry.

[10]  S. Dey,et al.  Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Joyce Cheung-Flynn,et al.  Physiological role for the cochaperone FKBP52 in androgen receptor signaling. , 2005, Molecular endocrinology.

[12]  T. Golub,et al.  Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. , 2005, The Journal of urology.

[13]  E. R. Sánchez,et al.  Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. , 2005, Biochemistry.

[14]  M. Sadar,et al.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 1. , 2005, The Journal of urology.

[15]  M. Sadar,et al.  Cell lines used in prostate cancer research: a compendium of old and new lines--part 2. , 2005, The Journal of urology.

[16]  D. Picard,et al.  The Hsp90‐binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo , 2003, The EMBO journal.

[17]  L. Gray,et al.  A novel cell line, MDA-kb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[18]  J. Steiner,et al.  Immunophilins: beyond immunosuppression. , 1998, Journal of medicinal chemistry.

[19]  D. Toft,et al.  Differential interactions of p23 and the TPR-containing proteins Hop, Cyp40, FKBP52 and FKBP51 with Hsp90 mutants. , 1998, Cell stress & chaperones.

[20]  B. Shoichet,et al.  Flexible ligand docking using conformational ensembles , 1998, Protein science : a publication of the Protein Society.

[21]  R. Rimerman,et al.  Molecular cloning of human FKBP51 and comparisons of immunophilin interactions with Hsp90 and progesterone receptor , 1997, Molecular and cellular biology.

[22]  Daniel A. Gschwend,et al.  Orientational sampling and rigid‐body minimization in molecular docking , 1993, Proteins.

[23]  Heather A Balsiger,et al.  Yeast-based reporter assays for the functional characterization of cochaperone interactions with steroid hormone receptors. , 2009, Methods in molecular biology.